Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical performance of Roche Cobas 4800 HPV Test.

Literature DB >> 24719443

Clinical performance of Roche Cobas 4800 HPV Test.

Miao Cui¹, Nicholas Chan¹, Momo Liu¹, Khanh Thai¹, Joanna Malaczynska¹, Ila Singh¹, David Zhang¹, Fei Ye².

Abstract

Evaluation of the Cobas 4800 test demonstrated that Cobas had a low rate of cross-reactivity with low-risk human papillomavirus (lrHPV), a 3.74% disconcordance rate between prealiquots and postaliquots, and failure rates of 4.57% and 1.16%, respectively, after vortexing and swirling. This study demonstrated that the Cobas test has good sensitivity, accuracy, and reproducibility for detecting 14 high-risk HPV (hrHPV) genotypes.

Entities: Species

Mesh：

Year: 2014 PMID： 24719443 PMCID： PMC4042746 DOI： 10.1128/JCM.00883-14

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

9 in total

1. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes.

Authors: Maria Luisa Mateos Lindemann; Mario Jose Rodriguez Dominguez; Jesús Chacón de Antonio; Maria Teresa Sandri; Alessio Tricca; Mario Sideri; Hacène Khiri; Sophie Ravet; Sean Boyle; Carrie Aldrich; Philippe Halfon
Journal: J Mol Diagn Date: 2011-11-10 Impact factor: 5.568

Review 2. Process of care failures in invasive cervical cancer: systematic review and meta-analysis.

Authors: Andrea R Spence; Patricia Goggin; Eduardo L Franco
Journal: Prev Med Date: 2007-06-22 Impact factor: 4.018

3. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.

Authors: Ni Li; Silvia Franceschi; Rebecca Howell-Jones; Peter J F Snijders; Gary M Clifford
Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396

4. Real time quantitative PCR.

Authors: C A Heid; J Stevens; K J Livak; P M Williams
Journal: Genome Res Date: 1996-10 Impact factor: 9.043

5. The global health burden of infection-associated cancers in the year 2002.

Authors: Donald Maxwell Parkin
Journal: Int J Cancer Date: 2006-06-15 Impact factor: 7.396

6. Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors: Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal: Int J Cancer Date: 2004-08-20 Impact factor: 7.396

Review 7. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

Authors: F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz
Journal: Vaccine Date: 2008-08-19 Impact factor: 3.641

8. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay.

Authors: Stephanie S Liu; Rebecca C Y Leung; Karen K L Chan; Annie N Y Cheung; Hextan Y S Ngan
Journal: J Clin Microbiol Date: 2009-12-30 Impact factor: 5.948

9. Simultaneous amplification and detection of specific DNA sequences.

Authors: R Higuchi; G Dollinger; P S Walsh; R Griffith
Journal: Biotechnology (N Y) Date: 1992-04

9 in total

16 in total

Review 1. Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors: Eileen M Burd
Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132

2. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.

Authors: M J Binnicker; B S Pritt; B J Duresko; M J Espy; T E Grys; M A Zarka; S E Kerr; M R Henry
Journal: J Clin Microbiol Date: 2014-08-13 Impact factor: 5.948

Review 3. Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines.

Authors: Ryan C V Lintao; Leslie Faye T Cando; Glenmarie Angelica S Perias; Ourlad Alzeus G Tantengco; Ian Kim B Tabios; Clarissa L Velayo; Sheriah Laine M de Paz-Silava
Journal: Front Med (Lausanne) Date: 2022-06-20

4. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Authors: Rong Wang; Xiao-Lei Guo; G Bea A Wisman; Ed Schuuring; Wen-Feng Wang; Zheng-Yu Zeng; Hong Zhu; Shang-Wei Wu
Journal: BMC Infect Dis Date: 2015-07-04 Impact factor: 3.090

5. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Authors: E Schuuring; G B A Wisman; A Boers; R Wang; R W van Leeuwen; H G Klip; G H de Bock; H Hollema; W van Criekinge; T de Meyer; S Denil; A G J van der Zee
Journal: Clin Epigenetics Date: 2016-03-09 Impact factor: 6.551

6. Comparison of the Cobas 4800 HPV and HPV 9G DNA Chip Tests for Detection of High-Risk Human Papillomavirus in Cervical Specimens of Women with Consecutive Positive HPV Tests But Negative Pap Smears.

Authors: Sun-Young Jun; Eun Su Park; Jiyoung Kim; Jun Kang; Jae Jun Lee; Yoonjin Bae; Sang-Il Kim; Lee-So Maeng
Journal: PLoS One Date: 2015-10-15 Impact factor: 3.240

7. Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests.

Authors: Keith D Tardif; Michael T Pyne; Elisabeth Malmberg; Tatum C Lunt; Robert Schlaberg
Journal: PLoS One Date: 2016-02-23 Impact factor: 3.240